The team at Curaleaf International is looking forward to attending the 34th Annual International Cannabinoid Research Society (ICRS) Symposium, taking place from June 30 – July 5, 2024, in Salamanca, Spain.
Dr. Simon Erridge, Research Director at Curaleaf Clinic, and Dr. Mikael Sodergren, Chief Medical Officer at Curaleaf International, will be attending this event for the fourth consecutive year. This conference is a platform for showcasing cutting-edge cannabinoid research and fostering collaboration among the world’s leading experts in the field.
Dr. Erridge will deliver a presentation on “Clinical Outcomes Analysis of Medical Cannabis for Chronic Cancer Pain.” This research delves into the outcomes of patients seen at Curaleaf Clinic with chronic cancer pain. He says: “With cancer affecting millions worldwide and pain being a significant problem for nearly 1 in 2 cancer patients, this study’s findings from the UK Medical Cannabis Registry help further build the evidence on how medical cannabis can be prescribed for patients with cancer.”
At the conference, we will also showcase seven poster presentations. These studies examine the impact and safety of medical cannabis on pain and overall health-related quality of life across a range of conditions, specifically – hypermobility, inflammatory arthritis, osteoarthritis, endometriosis, insomnia, depression, and inflammatory bowel disease (IBD).
The symposium is a great opportunity to meet fellow researchers, clinicians, and industry leaders at the ICRS Symposium, share our insights and explore new avenues for collaboration.
To find out more about the UK Medical Cannabis Registry’s latest research and publications visit – https://ukmedicalcannabisregistry.com/